Current Complaints | Help Center| Subscribe

Recent:

Data for the month ending - Aug, 2026

Sr. No.	Received from	Pending at the end of last month	Received	Resolved*	Total Pending #	Pending complaints >3months	Average Resolution time^ (in days)
1	Directly from Investors	0	0	0	0	0	0
2	SEBI (SCORES)	0	0	0	0	0	0
3	Other Sources (if any)	0	0	0	0	0	0
	Grand Total	0	0	0	0	0	0

^ Average Resolution time is the sum total of time taken to resolve each complaint in days, in the current month divided by total number of complaints resolved in the current month.

Trend of Monthly Disposal of Complaints

Sr. No.	Month	Carried forward from previous month	Received	Resolved*	Pending#
1	Jun, 2026	0	0	0	0
2	Jul, 2026	0	0	0	0
3	Aug, 2026	0	0	0	0
	Grand Total	0	0	0	0

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the month.

Trend of Annual Disposal of Complaints

Sr. No.	Fin. Year	Received	Resolved*
1	2022-23	1	1
2	2023-24	0	0
3	2024-25	0	0
4	2025-26	1	1
	Grand Total	2	2

*Inclusive of complaints of previous months resolved in the current month. #Inclusive of complaints pending as on the last day of the year.

NGL Fine Chem informs about board meeting

NGL Fine-Chem Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 524774 | NSE: NGLFINE

01 Nov 2021 Evaluate

NGL Fine-Chem has informed that the third Board Meeting for the financial year 2021-22 of the Board of Directors of NGL Fine-Chem will be held on Wednesday, 10th November, 2021 at the Registered Office of the Company at 301, E-Square, Subhash Road, Vile Parle East, Mumbai 400057 to transact the following business: to approve the unaudited Standalone Financial Results for the quarter and half year ended on 30th September, 2021; to approve the unaudited Consolidated Financial Results for the quarter and half year ended on 30th September, 2021; to approve the Statement of Assets & Liabilities for the half year ended on 30th September, 2021; to approve the Statement of Cash flow for the half year ended on 30th September, 2021; to approve the Statement of related party transactions for the half year ended on 30th September, 2021; and any other business with the permission of the chair.

The above information is a part of company’s filings submitted to BSE.

Peers

Company Name	CMP
Sun Pharma. Inds.	1743.00
Dr. Reddys Labs.	1224.50
Cipla	1337.00
Lupin	1925.00
Zydus Lifesciences	1127.85
View more..

Name of the IA registered with SEBI:	The Alchemists Ark Pvt. Ltd.
Logo:
Trade/Brand Name of IA:	MoneyWorks4Me Investment Advisers
Brand Logo:
SEBI Registration Number:	INA000013323 Validity – May 16, 2019 – Perpetual
Registration:	Non-Individual
BSE Enlistment No:	1187
Address:	B-101, Signet Corner Building, Balewadi Phata, Baner, Pune, Maharashtra 411045

Compliance Officer Details:	Name: Shrikant Jagtap Email: shrikant.jagtap@moneyworks4me.com	Telephone: +919860359463 Address: Same as IA
Grievance Officer Details:	Name: Mukta Vaze Email: mukta.vaze@moneyworks4me.com	Telephone: +919860919463 Address: Same as IA
Principal Officer Details:	Name: Atharva Bhide Email: atharva.bhide@moneyworks4me.com	Telephone: +919175899463 Address: Same as IA
Standard Warning:	Investment in securities market are subject to market risks. Read all the related documents carefully before investing.
Disclaimer:	Registration granted by SEBI, enlistment with exchange and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.